Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05757843
Title Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Indiana University
Indications
Therapies
Age Groups: senior | adult
Covered Countries


No variant requirements are available.